MannKind, one of the inhaled-insulin market’s only remaining players, has posted higher than expected Q4 losses as costs for development of its lead product candidate Afresa increase ahead of its submission to the US FDA.
Pfizer yesterday announced a multi-million dollar pay-off to
ex-partner Nektar Therapeutics, but the details of the deal reveal
not only Nektar's concerns for its future, but also that Pfizer is
still keeping its fingers in the...